|
US5266480A
(en)
*
|
1986-04-18 |
1993-11-30 |
Advanced Tissue Sciences, Inc. |
Three-dimensional skin culture system
|
|
US5219740A
(en)
*
|
1987-02-13 |
1993-06-15 |
Fred Hutchinson Cancer Research Center |
Retroviral gene transfer into diploid fibroblasts for gene therapy
|
|
US6048729A
(en)
|
1987-05-01 |
2000-04-11 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
US6140111A
(en)
*
|
1987-12-11 |
2000-10-31 |
Whitehead Institute For Biomedical Research |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
|
US6544771B1
(en)
|
1987-12-11 |
2003-04-08 |
Cell Genesys, Inc. |
Retroviral gene therapy vectors and therapeutic methods based thereon
|
|
US5591624A
(en)
*
|
1988-03-21 |
1997-01-07 |
Chiron Viagene, Inc. |
Retroviral packaging cell lines
|
|
US5716826A
(en)
*
|
1988-03-21 |
1998-02-10 |
Chiron Viagene, Inc. |
Recombinant retroviruses
|
|
US6133029A
(en)
|
1988-03-21 |
2000-10-17 |
Chiron Corporation |
Replication defective viral vectors for infecting human cells
|
|
US6645942B1
(en)
|
1988-04-28 |
2003-11-11 |
The Salk Institute For Biological Studies |
Somatic cell gene therapy
|
|
JPH04507041A
(ja)
*
|
1988-12-13 |
1992-12-10 |
アメリカ合衆国 |
遺伝工学により修飾された内皮細胞およびその利用方法
|
|
US5650148A
(en)
*
|
1988-12-15 |
1997-07-22 |
The Regents Of The University Of California |
Method of grafting genetically modified cells to treat defects, disease or damage of the central nervous system
|
|
ATE174514T1
(de)
*
|
1989-01-23 |
1999-01-15 |
Chiron Corp |
Rekombinante zellen für therapien von infektionen und hyperprolieferative störungen und deren herstellung
|
|
US7238673B2
(en)
|
1989-03-31 |
2007-07-03 |
The Regents Of The University Of Michigan |
Treatment of diseases by site-specific instillation of cells or site-specific transformation of cells and kits therefor
|
|
WO1990015863A1
(en)
*
|
1989-06-13 |
1990-12-27 |
The Board Of Directors Of The Leland Stanford Junior University |
Isolation growth and differentiation of human muscle cells
|
|
DE69033710T2
(de)
*
|
1989-10-24 |
2001-06-13 |
Chiron Corp. (N.D.Ges.D. Staates Delaware), Emeryville |
Sekretion vom mit Gamma-Interferon Signalpeptid gebundenen humänen Protein
|
|
WO1991012329A2
(en)
*
|
1990-02-12 |
1991-08-22 |
Board Of Regents, The University Of Texas System |
Satellite cell proliferation in adult skeletal muscle
|
|
US5817491A
(en)
*
|
1990-09-21 |
1998-10-06 |
The Regents Of The University Of California |
VSV G pseusdotyped retroviral vectors
|
|
US5618531A
(en)
|
1990-10-19 |
1997-04-08 |
New York University |
Method for increasing the viability of cells which are administered to the brain or spinal cord
|
|
WO1992015676A1
(en)
*
|
1991-03-08 |
1992-09-17 |
The Salk Institute For Biological Studies |
Somatic cell gene therapy
|
|
US6692737B1
(en)
|
1991-11-05 |
2004-02-17 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
NZ245015A
(en)
|
1991-11-05 |
1995-12-21 |
Transkaryotic Therapies Inc |
Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production
|
|
US6063630A
(en)
|
1991-11-05 |
2000-05-16 |
Transkaryotic Therapies, Inc. |
Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
|
|
US6054288A
(en)
*
|
1991-11-05 |
2000-04-25 |
Transkaryotic Therapies, Inc. |
In vivo protein production and delivery system for gene therapy
|
|
DE69228127T2
(de)
*
|
1991-11-15 |
1999-09-02 |
The Regents Of The University Of California |
Therapie des zentralnervensystems mit genetisch modifizierten zellen
|
|
ATE152915T1
(de)
*
|
1991-11-29 |
1997-05-15 |
Viagene Inc |
Immuntherapeutische vektorkonstrukte gegen krebs
|
|
US6297048B1
(en)
|
1992-02-04 |
2001-10-02 |
Chiron Corporation |
Hepatitis therapeutics
|
|
EP0630384A4
(de)
*
|
1992-02-28 |
1996-09-04 |
Brigham & Womens Hospital |
Methoden und verbindungen zur verhinderung der transplantat-abstossung.
|
|
US6531124B1
(en)
|
1992-07-10 |
2003-03-11 |
Transkaryotic Therapies, Inc. |
In vivo production and delivery of insulinotropin for gene therapy
|
|
US6670178B1
(en)
|
1992-07-10 |
2003-12-30 |
Transkaryotic Therapies, Inc. |
In Vivo production and delivery of insulinotropin for gene therapy
|
|
US5591625A
(en)
*
|
1993-11-24 |
1997-01-07 |
Case Western Reserve University |
Transduced mesenchymal stem cells
|
|
US5656605A
(en)
*
|
1994-01-26 |
1997-08-12 |
Institute Of Molecular Biology, Inc. |
Device to promote drug-induced nerve regeneration
|
|
EP0679402B1
(de)
*
|
1994-04-25 |
2003-09-10 |
Japan Science and Technology Corporation |
Hybridgel, das eine biologisch aktive Substanz sekretiert
|
|
US6150137A
(en)
|
1994-05-27 |
2000-11-21 |
Ariad Pharmaceuticals, Inc. |
Immunosuppressant target proteins
|
|
US5888814A
(en)
*
|
1994-06-06 |
1999-03-30 |
Chiron Corporation |
Recombinant host cells encoding TNF proteins
|
|
GB9419048D0
(en)
*
|
1994-09-20 |
1994-11-09 |
Watt Diana J |
Treatment of muscular disorders
|
|
US7597886B2
(en)
*
|
1994-11-07 |
2009-10-06 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7820798B2
(en)
*
|
1994-11-07 |
2010-10-26 |
Human Genome Sciences, Inc. |
Tumor necrosis factor-gamma
|
|
US7888466B2
(en)
|
1996-01-11 |
2011-02-15 |
Human Genome Sciences, Inc. |
Human G-protein chemokine receptor HSATU68
|
|
US6689757B1
(en)
|
1996-02-12 |
2004-02-10 |
M.L. Laboratories Plc |
Methods for vaccination and vaccines therefor
|
|
US5842477A
(en)
*
|
1996-02-21 |
1998-12-01 |
Advanced Tissue Sciences, Inc. |
Method for repairing cartilage
|
|
FR2746109B1
(fr)
|
1996-03-12 |
1998-04-17 |
Rhone Poulenc Rorer Sa |
Milieu pour la conservation de materiel biologique
|
|
AU765149B2
(en)
*
|
1996-04-08 |
2003-09-11 |
New York University Medical Center |
Method for gene transfer to the central nervous system
|
|
US6210664B1
(en)
|
1996-04-08 |
2001-04-03 |
New York University Medical Center |
Method for gene transfer to the central nervous system
|
|
US6027721A
(en)
*
|
1996-05-20 |
2000-02-22 |
Cytotherapeutics, Inc. |
Device and method for encapsulated gene therapy
|
|
US5932779A
(en)
|
1996-06-10 |
1999-08-03 |
Millennium Pharmaceuticals, Inc. |
Screening methods for compounds useful in the regulation of body weight
|
|
US5830850A
(en)
*
|
1996-08-28 |
1998-11-03 |
Mount Sinai School Of Medicine Of The City Of New York |
Methods for the treatment of bone resorption disorders, including osteoporosis
|
|
US6544523B1
(en)
|
1996-11-13 |
2003-04-08 |
Chiron Corporation |
Mutant forms of Fas ligand and uses thereof
|
|
GB9715085D0
(en)
*
|
1997-07-18 |
1997-09-24 |
Jahoda Amanda J |
Gene therapy vehicle
|
|
CA2308511C
(en)
|
1997-10-29 |
2016-01-19 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Use of transfected or transduced mammalian cells for treating bone pathologies
|
|
BR9813930A
(pt)
|
1997-11-06 |
2006-12-19 |
Chiron Spa |
antìgeno neisserial
|
|
ATE446368T1
(de)
|
1998-01-14 |
2009-11-15 |
Novartis Vaccines & Diagnostic |
Antigene aus neisseria meningitidis
|
|
DE69914463T2
(de)
|
1998-03-13 |
2004-11-11 |
The University Of British Columbia, Vancouver |
Therapeutische chemokine rezeptor antagonisten
|
|
CA2245224A1
(en)
|
1998-08-14 |
2000-02-14 |
Jiang-Hong Giong |
Chemokine receptor antagonists and chemotherapeutics
|
|
CA2305787A1
(en)
|
2000-05-09 |
2001-11-09 |
The University Of British Columbia |
Cxcr4 antagonist treatment of hematopoietic cells
|
|
ATE490980T1
(de)
|
1998-03-19 |
2010-12-15 |
Human Genome Sciences |
Der gemeinsamen gamma-kette ähnlicher zytokinrezeptor
|
|
MX343752B
(es)
|
1998-05-01 |
2016-11-22 |
Novartis Vaccines & Diagnostics Inc |
Antigenos de neisseria meningitidis y composiciones que los contienen.
|
|
IL142094A0
(en)
|
1998-09-29 |
2002-03-10 |
Gamida Cell Ltd |
Methods of controlling proliferation and differentiation of stem and progenitor cells
|
|
EP1121437B1
(de)
|
1998-10-15 |
2008-02-20 |
Novartis Vaccines and Diagnostics, Inc. |
Gene mit veränderter expression in metastatischen brust- oder dickdarm- krebszellen
|
|
EP1126812A4
(de)
*
|
1998-10-26 |
2005-10-12 |
Univ Massachusetts |
Behandlung der haut mit adenosin oder einem adenosinanalog
|
|
DK1141331T3
(da)
|
1998-12-16 |
2009-01-05 |
Novartis Vaccines & Diagnostic |
Human cyclinafhængig kinase (hPNQALRE)
|
|
AU2221600A
(en)
|
1998-12-31 |
2000-07-31 |
Chiron Corporation |
Improved expression of hiv polypeptides and production of virus-like particles
|
|
US7935805B1
(en)
|
1998-12-31 |
2011-05-03 |
Novartis Vaccines & Diagnostics, Inc |
Polynucleotides encoding antigenic HIV Type C polypeptides, polypeptides and uses thereof
|
|
DE19956568A1
(de)
|
1999-01-30 |
2000-08-17 |
Roland Kreutzer |
Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens
|
|
WO2000050620A2
(en)
|
1999-02-26 |
2000-08-31 |
Human Genome Sciences, Inc. |
Human endokine alpha and methods of use
|
|
JP2002538167A
(ja)
|
1999-03-03 |
2002-11-12 |
バイオジェン インコーポレイテッド |
脂質の代謝および貯蔵を調節する方法
|
|
AU774332B2
(en)
|
1999-03-12 |
2004-06-24 |
Gpc Biotech Inc. |
Methods and reagents for identifying synthetic genetic elements
|
|
US6328762B1
(en)
*
|
1999-04-27 |
2001-12-11 |
Sulzer Biologics, Inc. |
Prosthetic grafts
|
|
NZ571167A
(en)
|
1999-04-30 |
2010-05-28 |
Novartis Vaccines & Diagnostic |
Fragments from Neisseria protein ORF 953 and their use in medicaments and diagnostic reagents
|
|
GB9911683D0
(en)
|
1999-05-19 |
1999-07-21 |
Chiron Spa |
Antigenic peptides
|
|
US7396905B1
(en)
|
1999-05-21 |
2008-07-08 |
Mckeon Frank |
Calcipressins: endogenous inhibitors of calcineurin, uses and reagents related thereto
|
|
GB9916529D0
(en)
|
1999-07-14 |
1999-09-15 |
Chiron Spa |
Antigenic peptides
|
|
EP2275559A3
(de)
|
1999-09-28 |
2011-03-23 |
Shire Human Genetic Therapies, Inc. |
Optimierte Boten-RNA (mRNA)
|
|
PT2275551E
(pt)
|
1999-10-29 |
2015-06-29 |
Novartis Vaccines & Diagnostic |
Péptidos antigénicos de neisseria
|
|
DE10100586C1
(de)
|
2001-01-09 |
2002-04-11 |
Ribopharma Ag |
Verfahren zur Hemmung der Expression eines Ziegens
|
|
US6951839B1
(en)
|
1999-11-30 |
2005-10-04 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
|
US8168178B2
(en)
|
1999-11-30 |
2012-05-01 |
Curis, Inc. |
Methods and compositions for regulating lymphocyte activity
|
|
EP1626056B1
(de)
|
1999-12-30 |
2012-03-28 |
President and Fellows of Harvard College |
Verfahren und Zusammensetzungen zur Modulierung des Hepatozytenwachstums, der Differenzierung von Plasmazellen oder der Aktivität von T-Zellen durch Modulierung der Aktivität von XBP-1
|
|
ES2588917T3
(es)
|
2000-01-17 |
2016-11-07 |
Glaxosmithkline Biologicals Sa |
Vacuna de VME suplementada contra meningococo
|
|
US7368425B2
(en)
|
2006-03-24 |
2008-05-06 |
Chemokine Therapeutics Corp. |
Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
|
|
US7378098B2
(en)
|
2000-04-12 |
2008-05-27 |
The University Of British Columbia |
CXC chemokine receptor 4 agonist peptides
|
|
US20050059584A1
(en)
|
2002-08-16 |
2005-03-17 |
Ahmed Merzouk |
Novel chemokine mimetics synthesis and their use
|
|
WO2001082973A2
(en)
*
|
2000-04-28 |
2001-11-08 |
University Of Pittsburgh Of The Commonwealth System Of Higher Education |
Viral and non-viral vectors as vehicles for delivering transgenes for treating bone pathologies
|
|
US7585497B2
(en)
*
|
2000-05-17 |
2009-09-08 |
Oregon Health & Science University |
Induction of apoptosis and cell growth inhibition by protein 4.33
|
|
EP1294949A4
(de)
|
2000-06-15 |
2004-08-25 |
Human Genome Sciences Inc |
Menschlicher tumornekrosefaktor delta und epsilon
|
|
WO2001098543A2
(en)
*
|
2000-06-21 |
2001-12-27 |
Diadexus, Inc. |
Method of diagnosing, monitoring, staging, imaging and treating breast cancer
|
|
AU2002232593A1
(en)
*
|
2000-10-27 |
2002-05-06 |
Oregon Health And Science University |
Novel mutant igbp-3 molecules that do not bind to igfs, but retain their ability to functionally bind igfbp-3 receptor
|
|
US7939087B2
(en)
|
2000-10-27 |
2011-05-10 |
Novartis Vaccines And Diagnostics, Inc. |
Nucleic acids and proteins from Streptococcus groups A & B
|
|
US7423142B2
(en)
|
2001-01-09 |
2008-09-09 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
US7767802B2
(en)
|
2001-01-09 |
2010-08-03 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of anti-apoptotic genes
|
|
WO2002064612A2
(en)
|
2001-02-09 |
2002-08-22 |
Human Genome Sciences, Inc. |
Human g-protein chemokine receptor (ccr5) hdgnr10
|
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
|
JP2004536579A
(ja)
|
2001-04-13 |
2004-12-09 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
血管内皮増殖因子2
|
|
EP1404713A4
(de)
|
2001-05-24 |
2004-09-22 |
Human Dna Technology Inc |
Neues keratinocyte growth factor 2 analogon in haarfollikeln
|
|
AU2002320314A1
(en)
|
2001-07-05 |
2003-01-21 |
Chiron, Corporation |
Polynucleotides encoding antigenic hiv type c polypeptides, polypeptides and uses thereof
|
|
EP1409694A4
(de)
|
2001-07-05 |
2006-02-08 |
Chiron Corp |
Antigene typ-b- und/oder typ-c-hiv-polypeptide codierende polynukleotide, polypeptide und deren verwendungen
|
|
BR0211111A
(pt)
|
2001-07-12 |
2004-06-22 |
Univ Massachusetts |
Molécula de ácido nucleico isolada, vetor, célula hospedeira, transgene, precursor de rna engenheirado, animal transgênico não humano, e, método de induzir a interferência de ácido ribonucleico de um gene alvo em uma célula
|
|
EP1900815B1
(de)
|
2001-07-12 |
2016-09-07 |
University of Massachusetts |
In-vivo-Herstellung kleiner interferierender und Genverstummung vermittelnder RNAs
|
|
US7176278B2
(en)
|
2001-08-30 |
2007-02-13 |
Biorexis Technology, Inc. |
Modified transferrin fusion proteins
|
|
US7745418B2
(en)
|
2001-10-12 |
2010-06-29 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting viral replication
|
|
EP2002827A2
(de)
|
2001-12-05 |
2008-12-17 |
The Baylor College Of Medicine |
Verfahren und Zusammensetzungen zur Regulierung der Knochenbildung mittels Modulation des sympathischen Tonus
|
|
ES2386386T3
(es)
|
2001-12-12 |
2012-08-20 |
Novartis Vaccines And Diagnostics S.R.L. |
Inmunización contra Chlamydia trachomatis
|
|
US7049121B2
(en)
*
|
2001-12-20 |
2006-05-23 |
Applied Molecular Evolution |
Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
|
|
US6989261B2
(en)
*
|
2001-12-20 |
2006-01-24 |
Eli Lilly And Company |
Butyrylcholinesterase variant polypeptides with increased catalytic efficiency and methods of use
|
|
US7255874B1
(en)
|
2001-12-21 |
2007-08-14 |
Closure Medical Corporation |
Biocompatible polymers and adhesives: compositions, methods of making and uses related thereto
|
|
IL152904A0
(en)
|
2002-01-24 |
2003-06-24 |
Gamida Cell Ltd |
Utilization of retinoid and vitamin d receptor antagonists for expansion of renewable stem cell populations
|
|
EP1465982A4
(de)
|
2002-01-25 |
2006-06-07 |
Gamida Cell Ltd |
Verfahren zur expansion von stamm- und vorläuferzellen und damit erhaltene expandierte zellpopulationen
|
|
CA2421269A1
(en)
|
2002-08-09 |
2004-02-09 |
President And Fellows Of Harvard College |
Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
|
|
EP1572976B1
(de)
|
2002-11-21 |
2010-09-15 |
Celltech R & D, Inc. |
Modulieren von immunantworten
|
|
AU2003298920A1
(en)
*
|
2002-12-04 |
2004-06-23 |
Applied Molecular Evolution, Inc. |
Butyrylcholinesterase variants that alter the activity of chemotherapeutic agents
|
|
CA2802143C
(en)
|
2003-01-14 |
2018-06-19 |
Dana-Farber Cancer Institute |
Sparc encoding polynucleotide as a cancer therapy sensitizer
|
|
GB0308198D0
(en)
|
2003-04-09 |
2003-05-14 |
Chiron Srl |
ADP-ribosylating bacterial toxin
|
|
US7709207B2
(en)
|
2003-05-16 |
2010-05-04 |
Universite Laval |
Method for identifying compounds for treatment of pain
|
|
CA2527958C
(en)
|
2003-06-02 |
2014-04-08 |
University Of Massachusetts |
Methods and compositions for enhancing the efficacy and specificity of rnai
|
|
CA2528012C
(en)
|
2003-06-02 |
2015-11-24 |
University Of Massachusetts |
Methods and compositions for controlling efficacy of rna silencing
|
|
WO2005004794A2
(en)
|
2003-06-09 |
2005-01-20 |
Alnylam Pharmaceuticals Inc. |
Method of treating neurodegenerative disease
|
|
US7595306B2
(en)
*
|
2003-06-09 |
2009-09-29 |
Alnylam Pharmaceuticals Inc |
Method of treating neurodegenerative disease
|
|
AU2004245175C1
(en)
|
2003-06-10 |
2010-03-18 |
Biogen Ma Inc. |
Improved secretion of neublastin
|
|
DK1677735T3
(da)
|
2003-10-17 |
2014-10-27 |
Joslin Diabetes Center Inc |
Fremgangsmåder og sammensætninger til modulering af adipocytfunktion
|
|
AU2004283053A1
(en)
|
2003-10-20 |
2005-05-06 |
Nsgene A/S |
In vivo gene therapy of Parkinson's Disease
|
|
EP2476707B1
(de)
|
2003-11-14 |
2017-05-24 |
Children's Medical Center Corporation |
Selbstspaltende Ribozyme und ihre Verwendungen
|
|
ES2423060T3
(es)
|
2004-03-12 |
2013-09-17 |
Alnylam Pharmaceuticals, Inc. |
Agentes iRNA que tienen como diana al VEGF
|
|
KR101222281B1
(ko)
|
2004-03-29 |
2013-01-28 |
가르파마 컴퍼니 리미티드 |
신규 갈렉틴 9 개변체 단백질 및 그 용도
|
|
AU2005229434B2
(en)
|
2004-03-30 |
2010-09-30 |
Nsgene A/S |
Therapeutic use of a growth factor, NsG33
|
|
WO2005115435A2
(en)
*
|
2004-04-30 |
2005-12-08 |
Bas Medical, Inc. |
Methods and compositions for control of fetal growth via modulation of relaxin
|
|
EP1778842B8
(de)
|
2004-07-22 |
2012-03-21 |
Five Prime Therapeutics, Inc. |
Zusammensetzungen und verfahren zur verwendung von mgd-cdf zur krankheitsbehandlung
|
|
WO2006013462A2
(en)
*
|
2004-07-30 |
2006-02-09 |
Nsgene A/S |
Growth factors nsg28, nsg30, and nsg32
|
|
EP1789070B1
(de)
|
2004-08-03 |
2012-10-24 |
Biogen Idec MA Inc. |
Taj in der neuronalen funktion
|
|
AU2006214179A1
(en)
|
2005-02-17 |
2006-08-24 |
Biogen Idec Ma Inc. |
Treating neurological disorders
|
|
AU2006311725B2
(en)
|
2005-11-04 |
2011-11-24 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of NAV1.8 gene
|
|
CA2626690A1
(en)
|
2005-11-09 |
2007-05-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor v leiden mutant gene
|
|
PL1948798T3
(pl)
|
2005-11-18 |
2015-12-31 |
Glenmark Pharmaceuticals Sa |
Przeciwciała przeciwko integrynie alfa2 i ich zastosowania
|
|
US8846393B2
(en)
|
2005-11-29 |
2014-09-30 |
Gamida-Cell Ltd. |
Methods of improving stem cell homing and engraftment
|
|
JP5704741B2
(ja)
|
2006-03-31 |
2015-04-22 |
アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. |
Eg5遺伝子発現の抑制のための組成物および方法
|
|
WO2007127919A2
(en)
|
2006-04-28 |
2007-11-08 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of a gene from the jc virus
|
|
US7605251B2
(en)
|
2006-05-11 |
2009-10-20 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of the PCSK9 gene
|
|
EP2392583A1
(de)
|
2006-05-19 |
2011-12-07 |
Alnylam Europe AG. |
RNAi-Modulation von AHA und therapeutische Verwendungen davon
|
|
US7888498B2
(en)
|
2006-05-22 |
2011-02-15 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of IKK-B gene
|
|
CA2652815C
(en)
|
2006-05-25 |
2015-12-15 |
Biogen Idec Ma Inc. |
Methods of treating stroke
|
|
US8598333B2
(en)
|
2006-05-26 |
2013-12-03 |
Alnylam Pharmaceuticals, Inc. |
SiRNA silencing of genes expressed in cancer
|
|
DK2054431T3
(da)
|
2006-06-09 |
2012-01-02 |
Novartis Ag |
Konformere af bakterielle adhæsiner
|
|
US8664364B2
(en)
|
2007-01-24 |
2014-03-04 |
Carnegie Mellon University |
Optical biosensors
|
|
EP2139447A2
(de)
|
2007-03-20 |
2010-01-06 |
Harold Brem |
Gm-csf-kosmezeutikazusammensetzungen und verfahren zu ihrer verwendung
|
|
PE20090064A1
(es)
|
2007-03-26 |
2009-03-02 |
Novartis Ag |
Acido ribonucleico de doble cadena para inhibir la expresion del gen e6ap humano y composicion farmaceutica que lo comprende
|
|
EP2319926B1
(de)
|
2007-07-05 |
2016-08-31 |
Arrowhead Research Corporation |
DSRNA zur Behandlung viraler Infektionen
|
|
WO2009076400A2
(en)
|
2007-12-10 |
2009-06-18 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of factor vii gene
|
|
US20090176729A1
(en)
*
|
2007-12-14 |
2009-07-09 |
Alnylam Pharmaceuticals, Inc. |
Method of treating neurodegenerative disease
|
|
CN105267233B
(zh)
|
2008-03-05 |
2019-07-26 |
阿尔尼拉姆医药品有限公司 |
用于抑制Eg5和VEGF基因表达的组合物和方法
|
|
WO2009137613A2
(en)
|
2008-05-06 |
2009-11-12 |
Joslin Diabetes Center, Inc. |
Methods and compositions for inducing brown adipogenesis
|
|
US20090291073A1
(en)
*
|
2008-05-20 |
2009-11-26 |
Ward Keith W |
Compositions Comprising PKC-theta and Methods for Treating or Controlling Ophthalmic Disorders Using Same
|
|
EP2690175B1
(de)
|
2008-09-02 |
2016-12-28 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur kombinierten Hemmung der Expression eines mutierenden EGFR-Gens und IL-6
|
|
US20110287026A1
(en)
|
2008-09-23 |
2011-11-24 |
President And Fellows Of Harvard College |
Sirt4 and uses thereof
|
|
US8546554B2
(en)
|
2008-09-25 |
2013-10-01 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of Serum Amyloid A gene
|
|
EP2937418B1
(de)
|
2008-10-20 |
2017-10-18 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und Verfahren zur Hemmung der Expression des Transthyretin
|
|
JP6223659B2
(ja)
|
2008-11-10 |
2017-11-01 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
補体関連障害を処置するための方法および組成物
|
|
EP2373382B1
(de)
|
2008-12-10 |
2017-02-15 |
Alnylam Pharmaceuticals, Inc. |
Auf gnaq zielende dsrna-zusammensetzungen und verfahren zur unterdrückung der expression
|
|
WO2010080985A1
(en)
|
2009-01-08 |
2010-07-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for induced brown fat differentiation
|
|
WO2010083842A2
(en)
|
2009-01-23 |
2010-07-29 |
Nsgene A/S |
Expression of neuropeptides in mammalian cells
|
|
MX2011008936A
(es)
|
2009-02-24 |
2011-09-21 |
Alexion Pharma Inc |
Anticuerpos que contienen peptidos terapeuticos mimeticos de tpo/epo.
|
|
WO2010099341A1
(en)
|
2009-02-26 |
2010-09-02 |
Alnylam Pharmaceuticals, Inc. |
Compositions and methods for inhibiting expression of mig-12 gene
|
|
CA2754043A1
(en)
|
2009-03-12 |
2010-09-16 |
Alnylam Pharmaceuticals, Inc. |
Lipid formulated compositions and methods for inhibiting expression of eg5 and vegf genes
|
|
WO2010105311A1
(en)
|
2009-03-20 |
2010-09-23 |
Angioblast Systems, Inc. |
Production of reprogrammed pluripotent cells
|
|
WO2011005496A2
(en)
|
2009-06-22 |
2011-01-13 |
Massachusetts Eye & Ear Infirmary |
Islet1 (isl1) and hearing loss
|
|
WO2011050210A1
(en)
|
2009-10-21 |
2011-04-28 |
Agios Pharmaceuticals, Inc. |
Methods and compositions for cell-proliferation-related disorders
|
|
AU2010316982B2
(en)
|
2009-11-09 |
2013-09-12 |
Genepod Therapeutics Ab |
Novel viral vector construct for neuron specific continuous DOPA synthesis in vivo
|
|
WO2011088163A1
(en)
|
2010-01-14 |
2011-07-21 |
President And Fellows Of Harvard College |
Methods for modulating skeletal remodeling and patterning by modulating shn2 activity, shn3 activity, or shn2 and shn3 activity in combination
|
|
AU2011207348A1
(en)
|
2010-01-21 |
2012-08-02 |
Dana-Farber Cancer Institute, Inc. |
Context specific genetic screen platform to aid in gene discovery and target validation
|
|
US20130281510A1
(en)
|
2010-03-29 |
2013-10-24 |
Kumamoto University |
siRNA Therapy for Transthyretin (TTR) Related Ocular Amyloidosis
|
|
AU2011245117B2
(en)
|
2010-04-30 |
2015-03-12 |
Alexion Pharmaceuticals, Inc. |
Anti-C5a antibodies and methods for using the antibodies
|
|
JP6149226B2
(ja)
|
2010-10-01 |
2017-06-21 |
ホーバ セラピューティクス アンパルトセルスカブ |
アロディニア、痛覚過敏、自発痛及び幻肢痛の処置
|
|
WO2012051301A1
(en)
|
2010-10-12 |
2012-04-19 |
President And Fellows Of Harvard College |
Methods for identifying modulators of triglyceride metabolism, for modulating triglyceride metabolism and for identifying subjects at risk for abnormal triglyceride metabolism
|
|
US8815942B2
(en)
|
2010-10-20 |
2014-08-26 |
The Royal Institution For The Advancement Of Learning/Mcgill University |
Combination therapy and uses thereof for treatment and prevention of parasitic infection and disease
|
|
WO2012064743A2
(en)
|
2010-11-08 |
2012-05-18 |
The Johns Hopkins University |
Methods for improving heart function
|
|
EP3026432A3
(de)
|
2010-12-27 |
2016-07-27 |
Brown University |
Verfahren zur vorhersage der patientenreaktion auf eine behandlung mit biglycan
|
|
WO2012094511A2
(en)
|
2011-01-05 |
2012-07-12 |
Rhode Island Hospital |
Compositions and methods for the treatment of orthopedic disease or injury
|
|
EP2723351B1
(de)
|
2011-06-21 |
2018-02-14 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von protein-c (proc)-genen
|
|
EP2723756B1
(de)
|
2011-06-21 |
2020-03-11 |
Alnylam Pharmaceuticals, Inc. |
Zusammensetzungen und verfahren zur hemmung der expression von apolipoprotein-c-iii (apoc3)-genen
|
|
WO2013034157A1
(en)
|
2011-09-05 |
2013-03-14 |
Nsgene A/S |
Treatment of allodynia, hyperalgsia, spontaneous pain, and phantom pain
|
|
CA2848368C
(en)
|
2011-09-13 |
2023-02-14 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for brown fat induction and activity using fndc5
|
|
US10378060B2
(en)
|
2011-10-14 |
2019-08-13 |
Dana-Farber Cancer Institute, Inc. |
ZNF365/ZFP365 biomarker predictive of anti-cancer response
|
|
WO2013121426A1
(en)
|
2012-02-13 |
2013-08-22 |
Gamida-Cell Ltd. |
Culturing of mesenchymal stem cells
|
|
US9567569B2
(en)
|
2012-07-23 |
2017-02-14 |
Gamida Cell Ltd. |
Methods of culturing and expanding mesenchymal stem cells
|
|
US9175266B2
(en)
|
2012-07-23 |
2015-11-03 |
Gamida Cell Ltd. |
Enhancement of natural killer (NK) cell proliferation and activity
|
|
WO2014113540A1
(en)
|
2013-01-16 |
2014-07-24 |
Iowa State University Research Foundation, Inc. |
A deep intronic target for splicing correction on spinal muscular atrophy gene
|
|
EP2851086A1
(de)
|
2013-09-20 |
2015-03-25 |
Sanofi |
Serpine: Verfahren zur therapeutischen ß-Zellen-Regeneration und Funktion
|
|
WO2014128257A1
(en)
|
2013-02-22 |
2014-08-28 |
Sanofi |
Serpins: methods of therapeutic beta-cell regeneration and function
|
|
EP2769732A1
(de)
|
2013-02-22 |
2014-08-27 |
Sanofi |
Serpine: Verfahren zur therapeutischen Beta-Zellen-Regeneration und Funktion
|
|
BR112015023108A8
(pt)
|
2013-03-13 |
2018-01-23 |
Geneweave Biosciences Inc |
sistema de acondicionamento de célula bacteriana, método para acondicionamento de uma molécula de ácido nucléico repórter, composição, método para detectar uma presença ou uma ausência de uma célula bacteriana em uma amostra, vetor, método para detectar um transcrito alvo em uma célula, método para detectar a presença de uma célula bacteriana em uma amostra e kit.
|
|
WO2014201252A2
(en)
|
2013-06-13 |
2014-12-18 |
Shire Human Genetic Therapies, Inc. |
Messenger rna based viral production
|
|
EP3049521B1
(de)
|
2013-09-25 |
2019-03-06 |
Cornell University |
Verbindungen zur induzierung von antitumorimmunität und verfahren dafür
|
|
NZ711451A
(en)
|
2014-03-07 |
2016-05-27 |
Alexion Pharma Inc |
Anti-c5 antibodies having improved pharmacokinetics
|
|
EP3134546A4
(de)
|
2014-04-24 |
2017-12-06 |
Dana-Farber Cancer Institute, Inc. |
Tumorsuppressor und onkogene biomarker zur vorhersage der anti-immun-checkpoint-inhibitorreaktion
|
|
SMT202000715T1
(it)
|
2014-07-24 |
2021-01-05 |
Massachusetts Eye & Ear Infirmary |
Terapia genica rpgr per la retinite pigmentosa
|
|
US20170248603A1
(en)
|
2014-10-06 |
2017-08-31 |
Dana-Farber Cancer Institute, Inc. |
Angiopoiten-2 biomarkers predictive of anti-immune checkpoint response
|
|
AU2015328163B2
(en)
|
2014-10-09 |
2020-10-15 |
Dana-Farber Cancer Institute, Inc. |
Multiple-variable IL-2 dose regimen for treating immune disorders
|
|
US10034901B2
(en)
|
2015-01-22 |
2018-07-31 |
University Of Massachusetts |
Cancer immunotherapy
|
|
EP3250588A1
(de)
|
2015-01-29 |
2017-12-06 |
Board of Trustees of Michigan State University |
Kryptische polypeptide und verwendungen davon
|
|
HK1248812A1
(zh)
|
2015-03-06 |
2018-10-19 |
Dana-Farber Cancer Institute, Inc. |
预测在食管胃癌中pd-1通路抑制剂响应的pd-l2生物标记
|
|
US20180043034A1
(en)
|
2015-03-06 |
2018-02-15 |
Massachusetts Eye And Ear Infirmary |
Gene augmentation therapies for inherited retinal degeneration caused by mutations in the prpf31 gene
|
|
WO2016144917A1
(en)
|
2015-03-10 |
2016-09-15 |
University Of Massachusetts |
Targeting gdf6 and bmp signaling for anti-melanoma therapy
|
|
WO2016183183A1
(en)
|
2015-05-11 |
2016-11-17 |
The Johns Hopkins University |
Autoimmune antibodies for use in inhibiting cancer cell growth
|
|
US20180140626A1
(en)
|
2015-05-14 |
2018-05-24 |
Joslin Diabetes Center, Inc. |
Retinol-binding protein 3 (rbp3) as a protective factor in non-diabetic retinal degeneration
|
|
WO2017021359A1
(en)
|
2015-08-03 |
2017-02-09 |
Myodopa Limited |
Systemic synthesis and regulation of l-dopa
|
|
WO2017066796A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
WO2017066561A2
(en)
|
2015-10-16 |
2017-04-20 |
President And Fellows Of Harvard College |
Regulatory t cell pd-1 modulation for regulating t cell effector immune responses
|
|
WO2017066712A2
(en)
|
2015-10-16 |
2017-04-20 |
The Children's Medical Center Corporation |
Modulators of telomere disease
|
|
EP3368157B1
(de)
|
2015-10-29 |
2022-06-29 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur identifizierung, beurteilung, prävention und behandlung von stoffwechselerkrankungen mit verwendung von pm20d1 und n-lipidierten aminosäuren
|
|
CA3005878A1
(en)
|
2015-11-19 |
2017-05-26 |
The Brigham And Women's Hospital, Inc. |
Lymphocyte antigen cd5-like (cd5l)-interleukin 12b (p40) heterodimers in immunity
|
|
EP4310503A3
(de)
|
2015-12-30 |
2024-03-20 |
Momenta Pharmaceuticals, Inc. |
Verfahren im zusammenhang mit biologika
|
|
JP7215905B2
(ja)
*
|
2016-03-18 |
2023-01-31 |
プレシゲン,インコーポレイテッド |
Vii型コラーゲン欠損症の治療のための組成物及び方法
|
|
JP2019512271A
(ja)
|
2016-03-21 |
2019-05-16 |
デイナ ファーバー キャンサー インスティチュート,インコーポレイテッド |
T細胞疲弊状態特異的遺伝子発現調節因子およびその使用
|
|
EP3458579B1
(de)
|
2016-05-20 |
2023-07-05 |
Braingene AB |
Destabilisierung von domänen zur bedingten stabilisierung eines proteins
|
|
CA3024618A1
(en)
|
2016-05-27 |
2017-11-30 |
Alexion Pharmaceuticals, Inc. |
Methods for treatment of refractory generalized myasthenia gravis
|
|
WO2018001858A1
(en)
|
2016-06-27 |
2018-01-04 |
University Of Copenhagen |
Tailored assembly of a modular bud polypeptide
|
|
CA3034643A1
(en)
|
2016-09-20 |
2018-03-29 |
Ellen Weisberg |
Compositions and methods for identification, assessment, prevention, and treatment of aml using usp10 biomarkers and modulators
|
|
WO2018081817A2
(en)
|
2016-10-31 |
2018-05-03 |
University Of Massachusetts |
Targeting microrna-101-3p in cancer therapy
|
|
EP3609577B1
(de)
|
2017-04-14 |
2024-09-11 |
University of Massachusetts |
Braune fettselektive adipokine
|
|
WO2018226685A2
(en)
|
2017-06-06 |
2018-12-13 |
Dana-Farber Cancer Institute, Inc. |
Methods for sensitizing cancer cells to t cell-mediated killing by modulating molecular pathways
|
|
IL299348B2
(en)
|
2017-06-28 |
2025-05-01 |
Regeneron Pharma |
Antigen-binding proteins against human papillomavirus and methods of using them
|
|
ES2965486T3
(es)
|
2017-07-27 |
2024-04-15 |
Alexion Pharma Inc |
Formulaciones de anticuerpos anti-C5 de alta concentración
|
|
JP7518764B2
(ja)
|
2017-10-26 |
2024-07-18 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
発作性夜間ヘモグロビン尿症(PNH)および非典型溶血性尿毒症症候群(aHUS)の処置のための抗C5抗体の投薬量および投与
|
|
US11008602B2
(en)
|
2017-12-20 |
2021-05-18 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles and transduction particle-based reporter systems
|
|
EP3759125A4
(de)
|
2018-02-28 |
2021-12-08 |
Dana-Farber Cancer Institute, Inc. |
Verfahren zur krebsbehandlung unter verwendung von kombinationen aus anti-btnl2 und immuncheckpoint-blockierungsreagenzien
|
|
MX2020010094A
(es)
|
2018-04-06 |
2021-01-15 |
Dana Farber Cancer Inst Inc |
Kir3dl3 como receptor de hhla2, anticuerpos anti-hhla2 y usos de estos.
|
|
EP3790893A4
(de)
|
2018-05-11 |
2022-03-16 |
University Of Massachusetts |
Verfahren zur verbesserung der leptinempfindlichkeit zur behandlung von fettleibigkeit und diabetes
|
|
EP3802593B1
(de)
|
2018-05-31 |
2024-09-11 |
Alexion Pharmaceuticals, Inc. |
Dosierung und verabreichung von anti-c5 antikörpern zur behandlung von paroxysalen nocturalen hämoglobin-uria (pnh) in pädiatrischen patienten
|
|
WO2019229264A1
(en)
|
2018-06-01 |
2019-12-05 |
Sanofi |
Combination therapy for treating hepatitis b virus infection
|
|
EP3802603A1
(de)
|
2018-06-04 |
2021-04-14 |
Alexion Pharmaceuticals, Inc. |
Dosierung und verabreichung von anti-c5-antikörpern zur behandlung des atypischen hämolytisch-urämischen syndroms (ahus) bei kindern
|
|
JP7538723B2
(ja)
|
2018-06-28 |
2024-08-22 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗c5抗体の産生方法
|
|
LT4324851T
(lt)
|
2018-07-19 |
2025-10-10 |
|
Chimeriniai antigeno receptoriai, pasižymintys bcma specifiškumu, ir jų panaudojimas
|
|
US12296023B2
(en)
|
2018-08-16 |
2025-05-13 |
The Regents Of The University Of California |
Chemically and photochemically initiated cell membrane blebbing to induce cell vesicle production, modifications thereof, and uses thereof
|
|
CN113286650A
(zh)
|
2018-09-06 |
2021-08-20 |
动量制药公司 |
连续细胞培养方法
|
|
CN113454110B
(zh)
|
2018-10-23 |
2024-07-02 |
里珍纳龙药品有限公司 |
Ny-eso-1 t细胞受体和其使用方法
|
|
US12240893B2
(en)
|
2018-10-30 |
2025-03-04 |
Alexion Pharmaceuticals, Inc. |
Subcutaneous dosage and administration of anti-C5 antibodies for treatment of paroxysmal nocturnal hemoglobinuria (PNH)
|
|
WO2020120649A1
(en)
|
2018-12-13 |
2020-06-18 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Artificial antigen presenting cells that constitutively express an antigen along with a hla-class ii molecule
|
|
CN113227404A
(zh)
|
2018-12-27 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
用于检测鲍氏不动杆菌的非复制型转导颗粒和基于转导颗粒的报告系统
|
|
US11572595B2
(en)
|
2018-12-31 |
2023-02-07 |
Roche Molecular Systems, Inc. |
Non-replicative transduction particles with one or more non-native tail fibers and transduction particle-based reporter systems
|
|
KR20210131323A
(ko)
|
2018-12-31 |
2021-11-02 |
모멘타 파머슈티컬스 인코포레이티드 |
우스테키누맙 생성 방법
|
|
US20220289854A1
(en)
|
2019-04-30 |
2022-09-15 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating cancer using combinations of anti-cx3cr1 and immune checkpoint blockade agents
|
|
IT201900007060A1
(it)
|
2019-05-21 |
2020-11-21 |
St Superiore Di Sanita |
Cellule tumorali ingegnerizzate e loro usi
|
|
IT201900012540A1
(it)
|
2019-07-22 |
2021-01-22 |
Humanitas Mirasole Spa |
Inibitori di CHI3L1 e loro usi
|
|
BR112022001194A2
(pt)
|
2019-07-24 |
2022-06-07 |
Regeneron Pharma |
Receptores de antígeno quimérico com especificidade de mage a4 e usos dos mesmos
|
|
EP4021934A4
(de)
|
2019-08-30 |
2024-02-14 |
The Regents of the University of California |
Screening-methoden von genfragment-überexpressionen und ihre verwendungen
|
|
US20220356234A1
(en)
|
2019-10-02 |
2022-11-10 |
Alexion Pharmaceuticals, Inc. |
Complement inhibitors for treating drug-induced complement-mediated response
|
|
EP4037712A4
(de)
|
2019-10-04 |
2023-11-01 |
Albert Einstein College of Medicine |
Kir3dl3 ist ein hemmender rezeptor für das immunsystem und verwendungen davon
|
|
CA3163358A1
(en)
|
2019-12-03 |
2021-06-10 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins and uses thereof
|
|
BR112022010425A2
(pt)
|
2019-12-03 |
2022-08-23 |
Evotec Int Gmbh |
Proteínas de ligação ao antígeno associadas a interferon para uso no tratamento de infecção por hepatite b
|
|
PH12022551471A1
(en)
|
2019-12-20 |
2023-04-24 |
Momenta Pharmaceuticals Inc |
Antibodies against integrin alpha 11 beta 1
|
|
WO2021136752A1
(en)
|
2019-12-31 |
2021-07-08 |
F. Hoffmann-La Roche Ag |
Quantitative pcr screening of inducible prophage from bacterial isolates
|
|
BR112022014461A2
(pt)
|
2020-01-24 |
2022-09-13 |
Regeneron Pharma |
Antígeno preferencialmente expresso em receptores de células t de melanoma (prame) e métodos de uso dos mesmos
|
|
WO2021150925A1
(en)
|
2020-01-24 |
2021-07-29 |
Dana-Farber Cancer Institute, Inc. |
Uses of biomarkers for improving immunotherapy
|
|
US12129496B2
(en)
|
2020-02-12 |
2024-10-29 |
Massachusetts Eye And Ear Infirmary |
Haplotype-based treatment of RP1 associated retinal degenerations
|
|
CA3176425A1
(en)
|
2020-04-24 |
2021-10-28 |
Millennium Pharmaceuticals, Inc. |
Anti-cd19 antibodies and uses thereof
|
|
WO2021226063A1
(en)
|
2020-05-05 |
2021-11-11 |
Regeneron Pharmaceuticals, Inc. |
Car comprising cd28 zeta and cd3 zeta
|
|
CN116194478A
(zh)
|
2020-06-24 |
2023-05-30 |
阿雷克森制药公司 |
皮下(sc)施用抗c5抗体治疗补体相关病症
|
|
EP4211164A1
(de)
|
2020-09-14 |
2023-07-19 |
Vor Biopharma Inc. |
Einzeldomänenantikörper gegen cd33
|
|
WO2022076812A2
(en)
|
2020-10-09 |
2022-04-14 |
University Of Massachusetts |
Targeting nrip1 to alleviate metabolic disease
|
|
EP4343004A3
(de)
|
2020-10-19 |
2024-09-11 |
Dana-Farber Cancer Institute, Inc. |
Keimbahnbiomarker einer klinischen reaktion und nutzen für eine immuncheckpoint-inhibitortherapie
|
|
US20240024474A1
(en)
|
2020-11-13 |
2024-01-25 |
David Avigan |
Personalized fusion cell vaccines
|
|
KR20230121831A
(ko)
|
2020-12-18 |
2023-08-21 |
모멘타 파머슈티컬스 인코포레이티드 |
인테그린 알파 11 베타 1에 대한 항체
|
|
WO2022159793A2
(en)
|
2021-01-25 |
2022-07-28 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions for identifying neuroendocrine prostate cancer
|
|
JP7829595B2
(ja)
|
2021-04-09 |
2026-03-13 |
武田薬品工業株式会社 |
補体因子dを標的とする抗体及びその使用
|
|
PE20241789A1
(es)
|
2021-04-26 |
2024-09-06 |
Millennium Pharm Inc |
Anticuerpos anti-clec12a y usos de los mismos
|
|
AU2022266583A1
(en)
|
2021-04-26 |
2023-10-19 |
Millennium Pharmaceuticals, Inc. |
Anti-adgre2 antibodies and uses thereof
|
|
JP2024516308A
(ja)
|
2021-05-04 |
2024-04-12 |
リジェネロン・ファーマシューティカルズ・インコーポレイテッド |
Mage-a4特異性を有するキメラ抗原受容体及びその使用
|
|
JP2024518433A
(ja)
|
2021-05-06 |
2024-05-01 |
ホバ セラピューティクス エーピーエス |
化学療法誘発性神経障害性疼痛の予防及び治療
|
|
WO2022261183A2
(en)
|
2021-06-08 |
2022-12-15 |
Dana-Farber Cancer Institute, Inc. |
Compositions and methods for treating and/or identifying an agent for treating intestinal cancers
|
|
CA3220925A1
(en)
|
2021-06-09 |
2022-12-15 |
Kara Carter |
Interferon-associated antigen binding proteins for use for the treatment or prevention of coronavirus infection
|
|
AU2022372894A1
(en)
|
2021-10-20 |
2024-04-18 |
Takeda Pharmaceutical Company Limited |
Compositions targeting bcma and methods of use thereof
|
|
WO2023097119A2
(en)
|
2021-11-29 |
2023-06-01 |
Dana-Farber Cancer Institute, Inc. |
Methods and compositions to modulate riok2
|
|
KR20240118796A
(ko)
|
2021-12-10 |
2024-08-05 |
호바 세라퓨틱스 에이피에스 |
침해수용성 통증의 치료
|
|
CA3249166A1
(en)
|
2022-02-16 |
2023-08-24 |
The Johns Hopkins University |
METHODS FOR REDUCING PATHOLOGICAL ALPHA-SYNUCLEIN USING AGENTS THAT MODULATE FNDC5 OR BIOLOGICALLY ACTIVE FRAGMENTS THEREIN
|
|
JP2025513855A
(ja)
|
2022-04-11 |
2025-04-30 |
ブイオーアール バイオファーマ インコーポレーテッド |
結合剤及びその使用方法
|
|
WO2023240109A1
(en)
|
2022-06-07 |
2023-12-14 |
Regeneron Pharmaceuticals, Inc. |
Multispecific molecules for modulating t-cell activity, and uses thereof
|
|
WO2024091669A1
(en)
|
2022-10-28 |
2024-05-02 |
Ginkgo Bioworks, Inc. |
Chimeric antigen receptors comprising an intracellular domain pair
|
|
WO2024126294A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of parainfluenza virus infection
|
|
WO2024126293A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of respiratory syncytial virus infection
|
|
WO2024126289A1
(en)
|
2022-12-13 |
2024-06-20 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of influenza virus infection
|
|
AU2024223918A1
(en)
|
2023-02-17 |
2025-09-11 |
Regeneron Pharmaceuticals, Inc. |
Induced nk cells responsive to cd3/taa bispecific antibodies
|
|
WO2024206155A1
(en)
|
2023-03-24 |
2024-10-03 |
Cornell University |
Utilizing t cells derived from tumor draining lymph nodes for chimeric antigen receptor (car) t cell therapy for the treatment of cancer
|
|
WO2024213635A1
(en)
|
2023-04-12 |
2024-10-17 |
Evotec International Gmbh |
Interferon-associated antigen binding proteins for use for the treatment or prevention of hepatitis delta virus infection
|
|
EP4713363A1
(de)
|
2023-05-15 |
2026-03-25 |
Syzygymed Inc |
Egf-ähnliches modul mit mucin-ähnlichen hormon-like 2 (erm2)-bindenden mitteln und verfahren zur verwendung davon
|
|
EP4720109A1
(de)
|
2023-05-25 |
2026-04-08 |
Regeneron Pharmaceuticals, Inc. |
T-zell-rezeptoren, die präsentierte hpv16-, mart1-, cmv-, ebv- oder influenza-peptide binden
|
|
WO2025034542A1
(en)
|
2023-08-04 |
2025-02-13 |
Cornell University |
Gene signature panel predicting cancer response to immune checkpoint blockade and radiation therapy
|
|
WO2025255030A1
(en)
|
2024-06-03 |
2025-12-11 |
Cornell University |
Interferon gamma responsive chimeric t cell costimulatory receptor
|